Pharmacogenetics and forensic toxicology

Forensic Science International

Volumn 203, Issue 1-3, 2010, Pages 53-62

  Musshoff, Frank ^a   Stamer, Ulrike M ^b   Madea, Burkhard ^a  

^a Institute of Forensic Medicine   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antidepressants; Codeine; CYP2D6; Forensic toxicology; P450; Pharmacogenetics; Polymorphism; Tramadol

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; CARISOPRODOL; CODEINE; DIHYDROCODEINE; ETHYLMORPHINE; FENTANYL; FLUOXETINE; METHADONE; NALOXONE; OPIATE; OXYCODONE; PARACETAMOL; PHENYTOIN; TRAMADOL; VENLAFAXINE;

ANALGESIC ACTIVITY; APNEA; ARTICLE; CARDIOTOXICITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FATALITY; DRUG INTOXICATION; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSPORT; EPILEPTIC STATE; ETHNIC DIFFERENCE; FORENSIC TOXICOLOGY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAIR ANALYSIS; HEART ARREST; HUMAN; MUTATIONAL ANALYSIS; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RESPIRATORY TRACT INFECTION; SEDATION; SIDE EFFECT;

EID: 78649325566     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2010.07.011     Document Type: Article

References (111)

1. Eichelbaum M., Ingelman-Sundberg M., Evans W.E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 2006, 57:119-137.
2. Stamer U.M., Stuber F. The pharmacogenetics of analgesia. Expert Opin. Pharmacother. 2007, 8:2235-2245.
3. Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 2003, 348:529-537.
4. Evans W.E., McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 2003, 348:538-549.
5. Evans W.E., Relling M.V. Moving towards individualized medicine with pharmacogenomics. Nature 2004, 429:464-468.
6. Kupiec T.C., Raj V., Vu N. Pharmacogenomics for the forensic toxicologist. J. Anal. Toxicol. 2006, 30:65-72.
7. Sajantila A., Lunetta P., Ojanperä I. Postmortem pharmacokinetics: toward molecular autopsies. Pharmacogenomis and Proteomics: Enabling the Practice of Personalized Medicine 2006, 301-310. AACC Press, Washington, DC. S.H. Wong, M. Linder, R. Valdes (Eds.).
8. Nebert D.W. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?. Am. J. Hum. Genet. 1997, 60:265-271.
9. Nebert D.W., Adesnik M., Coon M.J., Estabrook R.W., Gonzalez F.J., Guengerich F.P., Gunsalus I.C., Johnson E.F., Kemper B., Levin W. The P450 gene superfamily: recommended nomenclature. DNA 1987, 6:1-11.
10. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., Nebert D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6:1-42.
11. Nelson D.R., Zeldin D.C., Hoffman S.M., Maltais L.J., Wain H.M., Nebert D.W. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004, 14:1-18.
12. Nelson D.R. The cytochrome p450 homepage. Hum. Genomics 2009, 4:59-65.
13. Zhou S.F., Chan E., Zhou Z.W., Xue C.C., Lai X., Duan W. Insights into the structure, function, and regulation of human cytochrome P450 1A2. Curr. Drug Metab. 2009, 10:713-729.
14. Wang B., Zhou S.F. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr. Med. Chem. 2009, 16:4066-4218.
15. Zhou S.F., Yang L.P., Zhou Z.W., Liu Y.H., Chan E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009, 11:481-494.
16. Zhou S.F., Wang B., Yang L.P., Liu J.P. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab. Rev. 2010, 42:268-354.
17. Di Y.M., Chow V.D., Yang L.P., Zhou S.F. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr. Drug Metab. 2009, 10:754-780.
18. Wang H., Tompkins L.M. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug Metab. 2008, 9:598-610.
19. Mo S.L., Liu Y.H., Duan W., Wei M.Q., Kanwar J.R., Zhou S.F., Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6 Curr. Drug Metab. 2009, 10:730-753.
20. Sistonen J., Fuselli S., Palo J.U., Chauhan N., Padh H., Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet. Genomics 2009, 19:170-179.
21. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet. 2009, 48:689-723.
22. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin. Pharmacokinet. 2009, 48:761-804.
23. Wang B., Yang L.P., Zhang X.Z., Huang S.Q., Bartlam M., Zhou S.F. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab. Rev. 2009, 41:573-643.
24. Zhou S.F., Liu J.P., Lai X.S. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr. Med. Chem. 2009, 16:2661-2805.
25. Neafsey P., Ginsberg G., Hattis D., Johns D.O., Guyton K.Z., Sonawane B. Genetic polymorphism in CYP2E1: population distribution of CYP2E1 activity. J. Toxicol. Environ. Health B Crit. Rev. 2009, 12:362-388.
26. Zhou S.F., Xue C.C., Yu X.Q., Li C., Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit. 2007, 29:687-710.
27. Zhou S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 2008, 9:310-322.
28. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 2007, 116:496-526.
29. Shitara Y., Horie T., Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 2006, 27:425-446.
30. Endres C.J., Hsiao P., Chung F.S., Unadkat J.D. The role of transporters in drug interactions. Eur. J. Pharm. Sci. 2006, 27:501-517.
31. Maeda K., Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet. 2008, 23:223-235.
32. Franke R.M., Gardner E.R., Sparreboom A. Pharmacogenetics of drug transporters. Curr. Pharm. Des. 2010, 16(2):220-230. see also http://www.membranetransport.org/ (accessed 31.03.10).
33. Kroetz D.L., Yee S.W., Giacomini K.M. The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin. Pharmacol. Ther. 2010, 87:109-116.
34. Wishart D.S., Knox C., Guo A.C., Cheng D., Shrivastava S., Tzur D., Gautam B., Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008, 36:D901-D906.
35. Gao Z., Li H., Zhang H., Liu X., Kang L., Luo X., Zhu W., Chen K., Wang X., Jiang H. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008, 9:104.
36. Zhu F., Han B., Kumar P., Liu X., Ma X., Wei X., Huang L., Guo Y., Han L., Zheng C., Chen Y. Update of TTD: therapeutic target database. Nucleic Acids Res. 2010, 38:D787-D791.
37. D.A. Flockhart, Cytochrome P450 Drug Interaction Table. Version 5.0 (2009) (accessed 31.03.10). http://medicine.iupui.edu/clinpharm/ddis/table.asp.
38. Zheng C.J., Zhou H., Xie B., Han L.Y., Yap C.W., Chen Y.Z. TRMP: a database of therapeutically relevant multiple pathways. Bioinformatics 2004, 20:2236-2241.
39. Frolkis A., Knox C., Lim E., Jewison T., Law V., Hau D.D., Liu P., Gautam B., Ly S., Guo A.C., Xia J., Liang Y., Shrivastava S., Wishart D.S. SMPDB: the small molecule pathway database. Nucleic Acids Res. 2010, 38:D480-D487.
40. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95. Biomarkers Definitions Working Group.
41. Marrer E., Dieterle F. Impact of biomarker development on drug safety assessment. Toxicol. Appl. Pharmacol. 2010, 243:167-179.
42. Swenberg J.A., Fryar-Tita E., Jeong Y.C., Boysen G., Starr T., Walker V.E., Albertini R.J. Biomarkers in toxicology and risk assessment: informing critical dose-response relationships. Chem. Res. Toxicol. 2008, 21:253-265.
43. Foster W.R., Chen S.J., He A., Truong A., Bhaskaran V., Nelson D.M., Dambach D.M., Lehman-McKeeman L.D., Car B.D. A retrospective analysis of toxicogenomics in the safety assessment of drug candidates. Toxicol. Pathol. 2007, 35:621-635.
44. Mendrick D.L. Genomic and genetic biomarkers of toxicity. Toxicology 2008, 245:175-181.
45. Amacher D.E. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol. Appl. Pharmacol. 2010.
46. Bradford L.D., Gaedigk A., Leeder J.S. High frequency of CYP2D6 poor and " intermediate" metabolizers in black populations: a review and preliminary data. Psychopharmacol. Bull. 1998, 34:797-804.
47. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3:229-243.
48. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev. 2003, 35:99-106.
49. Ozawa S., Soyama A., Saeki M., Fukushima-Uesaka H., Itoda M., Koyano S., Sai K., Ohno Y., Saito Y., Sawada J. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. 2004, 19:83-95.
50. Shah R.R. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2005, 360:1617-1638.
51. Kaneko A., Lum J.K., Yaviong L., Takahashi N., Ishizaki T., Bertilsson L., Kobayakawa T., Bjorkman A. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics 1999, 9:581-590.
52. Xie H.G., Prasad H.C., Kim R.B., Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 2002, 54:1257-1270.
53. Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002, 12:251-263.
54. Scordo M.G., Aklillu E., Yasar U., Dahl M.L., Spina E., Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol. 2001, 52:447-450.
55. Lin H.J., Han C.Y., Lin B.K., Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994, 4:125-134.
56. Hon Y.Y., Fessing M.Y., Pui C.H., Relling M.V., Krynetski E.Y., Evans W.E. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum. Mol. Genet. 1999, 8:371-376.
57. Collie-Duguid E.S., Pritchard S.C., Powrie R.H., Sludden J., Collier D.A., Li T., McLeod H.L. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999, 9:37-42.
58. Chowbay B., Cumaraswamy S., Cheung Y.B., Zhou Q., Lee E.J. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003, 13:89-95.
59. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., Taylor A., Xie H.G., McKinsey J., Zhou S., Lan L.B., Schuetz J.D., Schuetz E.G., Wilkinson G.R. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001, 70:189-199.
60. Drysdale C.M., McGraw D.W., Stack C.B., Stephens J.C., Judson R.S., Nandabalan K., Arnold K., Ruano G., Liggett S.B. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10483-10488.
61. Lotrich F.E., Pollock B.G., Ferrell R.E. Serotonin transporter promoter polymorphism in African Americans: allele frequencies and implications for treatment. Am. J. Pharmacogenomics 2003, 3:145-147.
62. Holmgren P., Ahlner J. Pharmacogenomics for forensic toxicology: Swedish experience. Pharmacogenomics and Proteomics 2006, 295-299. AACC Press, Washington, DC. S.H. Wong, M. Linder, R. Valdes (Eds.).
63. Skopp G. Preanalytic aspects in postmortem toxicology. Forensic Sci. Int. 2004, 142:75-100.
64. Drummer O.H. Postmortem toxicology of drugs of abuse. Forensic Sci. Int. 2004, 142:101-113.
65. Drummer O.H. Post-mortem toxicology. Forensic Sci. Int. 2007, 165:199-203.
66. Ferner R.E. Post-mortem clinical pharmacology. Br. J. Clin. Pharmacol. 2008, 66:430-443.
67. Skopp G. Postmortem toxicology. Forensic Sci. Med. Pathol. 2010, (Epub ahead of print).
68. Lotsch J., Skarke C., Liefhold J., Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin. Pharmacokinet. 2004, 43:983-1013.
69. Stamer U.M., Musshoff F., Kobilay M., Madea B., Hoeft A., Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin. Pharmacol. Ther. 2007, 82:41-47.
70. Kirchheiner J., Keulen J.T., Bauer S., Roots I., Brockmoller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J. Clin. Psychopharmacol. 2008, 28:78-83.
71. Stamer U.M., Stuber F., Muders T., Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth. Analg. 2008, 107:926-929.
72. Levo A., Koski A., Ojanpera I., Vuori E., Sajantila A., Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci. Int. 2003, 135:9-15.
73. Poulsen L., Brosen K., Rendt-Nielsen L., Gram L.F., Elbaek K., Sindrup S.H. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur. J. Clin. Pharmacol. 1996, 51:289-295.
74. Poulsen L., Riishede L., Brosen K., Clemensen S., Sindrup S.H. Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. Eur. J. Clin. Pharmacol. 1998, 54:451-454.
75. Eckhardt K., Li S., Ammon S., Schanzle G., Mikus G., Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998, 76:27-33.
76. Gasche Y., Daali Y., Fathi M., Chiappe A., Cottini S., Dayer P., Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 2004, 351:2827-2831.
77. Koren G., Cairns J., Chitayat D., Gaedigk A., Leeder S.J. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006, 368:704.
78. Voronov P., Przybylo H.J., Jagannathan N. Apnea in a child after oral codeine: a genetic variant-an ultra-rapid metabolizer. Paediatr. Anaesth. 2007, 17:684-687.
79. Hermanns-Clausen M., Weinmann W., Auwarter V., Ferreiros N., Trittler R., Muller C., Pahl A., Superti-Furga A., Hentschel R. Drug dosing error with drops: severe clinical course of codeine intoxication in twins. Eur. J. Pediatr. 2009, 168:819-824.
80. Ferreiros N., Dresen S., Hermanns-Clausen M., Auwaerter V., Thierauf A., Muller C., Hentschel R., Trittler R., Skopp G., Weinmann W. Fatal and severe codeine intoxication in 3-year-old twins-interpretation of drug and metabolite concentrations. Int. J. Legal Med. 2009, 123:387-394.
81. Fromm M.F., Hofmann U., Griese E.U., Mikus G. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. Clin. Pharmacol. Ther. 1995, 58:374-382.
82. Wilder-Smith C.H., Hufschmid E., Thormann W. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers. Br. J. Clin. Pharmacol. 1998, 45:575-581.
83. Zwisler S.T., Enggaard T.P., Mikkelsen S., Brosen K., Sindrup S.H. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol. Scand. 2010, 54:232-240.
84. Jannetto P.J., Wong S.H., Gock S.B., Laleli-Sahin E., Schur B.C., Jentzen J.M. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. J. Anal. Toxicol. 2002, 26:438-447.
85. Druid H., Holmgren P., Carlsson B., Ahlner J. Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results. Forensic Sci. Int. 1999, 99:25-34.
86. Helland A., Isaksen C.V., Slordal L. Death of a 10-month-old boy after exposure to ethylmorphine. J. Forensic Sci. 2010, 55:551-553.
87. Wong S.H., Wagner M.A., Jentzen J.M., Schur C., Bjerke J., Gock S.B., Chang C.C. Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity?. J. Forensic Sci. 2003, 48:1406-1415.
88. Eap C.B., Crettol S., Rougier J.S., Schlapfer J., Sintra G.L., Deglon J.J., Besson J., Croquette-Krokar M., Carrupt P.A., Abriel H. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin. Pharmacol. Ther. 2007, 81:719-728.
89. Guitton J., Buronfosse T., Desage M., Lepape A., Brazier J.L., Beaune P. Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem. Pharmacol. 1997, 53:1613-1619.
90. Jin M., Gock S.B., Jannetto P.J., Jentzen J.M., Wong S.H. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J. Anal. Toxicol. 2005, 29:590-598.
91. Schwab M., Seyringer E., Brauer R.B., Hellinger A., Griese E.U. Fatal MDMA intoxication. Lancet 1999, 353:593-594.
92. Gilhooly T.C., Daly A.K. CYP2D6 deficiency, a factor in ecstasy related deaths?. Br. J. Clin. Pharmacol. 2002, 54:69-70.
93. Kreth K., Kovar K., Schwab M., Zanger U.M. Identification of the human cytochromes P450 involved in the oxidative metabolism of " Ecstasy" -related designer drugs. Biochem. Pharmacol. 2000, 59:1563-1571.
94. Kraemer T., Maurer H.H. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther. Drug Monit. 2002, 24:277-289.
95. Salle F.R., DeVane C.L., Ferrell R.E. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J. Child Adolesc. Psychopharmacol. 2000, 10(1):27-34.
96. Koski A., Sistonen J., Ojanpera I., Gergov M., Vuori E., Sajantila A. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic Sci. Int. 2006, 158:177-183.
97. Thieme D., Rolf B., Sachs H., Schmid D. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int. J. Legal Med. 2008, 122:149-155.
98. Koski A., Ojanpera I., Sistonen J., Vuori E., Sajantila A. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am. J. Forensic Med. Pathol. 2007, 28:259-261.
99. Wijnen P.A., Limantoro I., Drent M., Bekers O., Kuijpers P.M., Koek G.H. Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity. Ann. Clin. Biochem. 2009, 46:527-530.
100. Launiainen T., Rasanen I., Vuori E., Ojanperä I. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int. J. Legal Med. 2010, (Epub ahead of print).
101. Kobylecki C.J., Hansen T., Timm S., Wang A., Jakobsen K.D., Sorensen H.J., Rasmussen H.B., Werge T. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study. Ther. Drug Monit. 2008, 30:265-270.
102. Anderson G.D. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther. Drug Monit. 2008, 30:173-180.
103. Kirchheiner J., Bertilsson L., Bruus H., Wolff A., Roots I., Bauer M. Individualized medicine-implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 2003, 3(36 Suppl.):S235-S243.
104. Spina E., Santoro V., D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin. Ther. 2008, 30:1206-1227.
105. Kirchheiner J., Seeringer A., Viviani R. Pharmacogenetics in psychiatry-a useful clinical tool or wishful thinking for the future?. Curr. Pharm. Des. 2010, 16:136-144.
106. Kleine-Brueggeney M., Musshoff F., Stuber F., Stamer U.M. Pharmacogenetics in palliative care. Forensic Sci. Int. 2010, 203:63-70.
107. Jannetto P.J., Bratanow N.C. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics 2009, 10(7):1157-1167.
108. Stamer U.M., Zhang L., Stuber F. Personalized therapy in pain management: where do we stand?. Pharmacogenomics 2010, 11(6):843-864.
109. Bramness J.G., Skurtveit S., Fauske L., Grung M., Molven A., Morland J., Steen V.M. Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects?. Pharmacogenetics 2003, 13:383-388.
110. Karch S.B. Changing times: DNA resequencing and the " nearly normal autopsy" J. Forensic Leg. Med. 2007, 14:389-397.
111. Budowle B., van D.A. Extracting evidence from forensic DNA analyses: future molecular biology directions. Biotechniques 2009, 46:339-350.